Cancer Advisor

Introduction: Can Low-Dose Naltrexone (LDN) Play a Role in Cancer Treatment? Low-dose naltrexone (LDN) has emerged as one of the most discussed repurposed drugs in integrative oncology—drawing attention from researchers, clinicians, and patients seeking safer, adjunctive cancer therapies. Originally developed as a high-dose medication to treat opioid and alcohol dependence, naltrexone behaves very differently when used at much lower doses (typically 1–5 mg daily), triggering unique biological effects that may influence cancer biology. Unlike conventional chemotherapy, which directly targets rapidly dividing cells, LDN appears to work through indirect mechanisms—modulating the immune system, altering inflammatory pathways, and influencing cellular signaling involved in tumor growth. One of the most studied mechanisms involves the opioid growth factor (OGF)–opioid growth factor receptor (OGFr) axis , a regulatory pathway that plays a key role in controlling cell proliferation. By transie...

Quick Answer Ivermectin and mebendazole are inexpensive generic drugs on their own — so the real question isn't "why does this cost more than the raw chemical," it's "what am I actually getting for that difference." The honest answer is verified potency, correct human dosing, physician screening for contraindications, and a documented chain of custody. Those are the things that go missing with unregulated or veterinary-labeled sources, and they're not minor details — they're the difference between a controlled dose and a guess. Why "Cheaper" Isn't the Same Product It's a fair instinct to look at a compounded prescription and compare it to what the same active ingredients cost elsewhere. But with ivermectin and mebendazole specifically, the price gap usually reflects a difference in what's actually being sold — not just markup. Here's the ...

A critical spotlight on the standout cases from our 760-case compilation — including the most heavily pretreated, "no options left" patients — with an honest look at what the evidence can and cannot tell us. Quick Answer Of the 760 case reports describing antiparasitic drug protocols (fenbendazole, ivermectin, or mebendazole) in patients with cancer, the most clinically notable outcomes fall into three broad categories: (1) rapid complete or near-complete remissions in patients whose disease had progressed despite conventional therapy, (2) imaging-confirmed tumor regressions ranging from 40% to 99%, and (3) patients receiving hospice care or given a prognosis of only weeks to live who survived substantially longer than expected. Only a small fraction of these 760 cases have been published in peer-reviewed journals; the remainder are self-reported anecdotal accounts. Accordingly, these reports should be regarded as hypothesis-generating observations rather than evid...